© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Assembly Biosciences, Inc. (ASMB) stock surged +2.88%, trading at $17.50 on NASDAQ, up from the previous close of $17.01. The stock opened at $17.28, fluctuating between $17.28 and $18.21 in the recent session.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Employees | 65 |
Beta | 0.646 |
Sales or Revenue | $7.16M |
5Y Sales Change% | 1.41% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Assembly Biosciences, Inc. (NASDAQ: ASMB) stock price is $17.50 in the last trading session. During the trading session, ASMB stock reached the peak price of $18.21 while $17.28 was the lowest point it dropped to. The percentage change in ASMB stock occurred in the recent session was 2.88% while the dollar amount for the price change in ASMB stock was $0.49.
The NASDAQ listed ASMB is part of Biotechnology industry that operates in the broader Healthcare sector. Assembly Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. William E. Delaney IV, Ph.D.
Chief Scientific Officer
Ms. Michele Anderson
Chief Devel. Officer
Amy Figueroa C.F.A.
Investor Relations Consultant
Dr. John G. McHutchison A.O., FRACP, M.D.
Chief Executive Officer & Director
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR
Chief HR Officer
Dr. Adam Zlotnick
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Mr. Jason A. Okazaki
Chief Operating Officer, Chief Executive Officer, Pres & Director
Mr. Thomas E. Rollins
Executive Officer
Dr. Tharaknath Rao
Head of Microbiome Clinical Devel. & Senior Vice President
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Dr. Richard J. Colonno
Senior Advisor
Jeanette M Bjorkquist
Executive Director of Accounting & Treasury
Shannon Ryan
Senior Vice President of Investor Relations, Corporation Affairs & Alliance Management
ASMB's closing price is 121.48% higher than its 52-week low of $7.68 where as its distance from 52-week high of $20.04 is -15.12%.
Number of ASMB employees currently stands at 65.
Official Website of ASMB is: https://www.assemblybio.com
ASMB could be contacted at phone 833 509 4583 and can also be accessed through its website. ASMB operates from 331 Oyster Point Boulevard, South San Francisco, CA 94080, United States.
ASMB stock volume for the day was 15.99K shares. The average number of ASMB shares traded daily for last 3 months was 23.07K.
The market value of ASMB currently stands at $111.05M with its latest stock price at $17.50 and 6.35M of its shares outstanding.